The Relationship Between the Antiphospholipid Syndrome and Heparin-Induced Thrombocytopenia

Hematology/Oncology Clinics of North America

Volumn 22, Issue 1, 2008, Pages 1-18

  Hoppensteadt, Debra A ^a   Walenga, Jeanine M ^a  

^a LOYOLA UNIVERSITY CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBIN III; BETA2 GLYCOPROTEIN 1; BIOLOGICAL MARKER; CARDIOLIPIN ANTIBODY; HEPARIN; LUPUS ANTICOAGULANT; PHOSPHATIDYLCHOLINE; PHOSPHATIDYLETHANOLAMINE; PHOSPHATIDYLGLYCEROL; PHOSPHATIDYLINOSITOL; PHOSPHATIDYLSERINE; PHOSPHOLIPID ANTIBODY; PROSTACYCLIN; PROTEIN C; PROTEIN S; THROMBOPLASTIN;

ANTIPHOSPHOLIPID SYNDROME; BLOOD CLOTTING DISORDER; CELL INTERACTION; CLINICAL FEATURE; DOWN REGULATION; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; FIBRINOLYSIS; HEMOSTASIS; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; IMMUNE RESPONSE; INFLAMMATION; LEUKOCYTE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; THROMBOCYTE ACTIVATION; THROMBOCYTOPENIA; UPREGULATION;

ANTIBODIES, ANTIPHOSPHOLIPID; ANTIPHOSPHOLIPID SYNDROME; ENDOTHELIUM, VASCULAR; HEPARIN; HUMANS; PLATELET ACTIVATION; RECEPTORS, FC; THROMBOCYTOPENIA; THROMBOPHILIA;

EID: 38149101722     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hoc.2007.11.001     Document Type: Review

References (80)

1. Arnout J. The pathogenesis of the antiphospholipid syndrome: a hypothesis based on parallelisms with heparin-induced-thrombocytopenia. Thromb Haemost 75 4 (1996) 536-541
2. Vermylen J., Hoylaerts J.F., and Arnout J. Antibody-mediated thrombosis. Thromb Haemost 78 1 (1997) 420-426
3. Bick R.L., Jakway J., and Baker W.F. Deep vein thrombosis: prevalence of etiologic factors and results of management in 100 consecutive patients. Semin Thromb Hemost 18 (1992) 267-274
4. Bick R.L., and Baker W.F. Anticardiolipin antibodies and thrombosis. Hematol Oncol Clin North Am 6 (1992) 1287-1299
5. Bick R.L. Antiphospholipid thrombosis syndromes. Hematol Oncol Clin North Am 17 1 (2003) 115-147
6. Kunkel L.A. Acquired circulating anticoagulants. Hematol Oncol Clin North Am 6 (1992) 1341-1357
7. Alving B.M. Antiphospholipid syndrome, lupus anticoagulants, and anticardiolipin antibodies. In: Loscalzo J., and Schafer A.I. (Eds). Thrombosis and hemorrhage. 2nd edition (1998), Williams & Wilkins, Baltimore 817-833
8. Triplett D.A. Antiphospholipid antibodies and thrombosis. A consequence, coincidence, or cause?. Arch Pathol Lab Med 117 (1993) 78-88
9. Bevers E.M., Galli M., Barbui T., et al. Lupus anticoagulant IgG's are not directed to phospholipids only, but to a complex of lipid-bound human prothrombin. Thromb Haemost 66 (1991) 629-632
10. McNeil H.P., Simpson R.J., and Chesterman C.N. Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: β2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci U S A 87 (1990) 4120-4124
11. Matsuura E., Igarashi Y., Fujimoto M., et al. Anticardiolipin cofactor(s) and differential diagnosis of autoimmune disease. Lancet 336 (1990) 177-178
12. Nakamura N., Kuragaki C., Shidara Y., et al. Antibody to annexin V has anti-phospholipid and lupus anticoagulant properties. Am J Hematol 49 (1995) 347-348
13. Oosting J.D., Derksen R.H.W.M., Bobbick I.W.G., et al. Antiphospholipid antibodies directed against a combination of phospholipids with prothrombin, protein C or protein S. An explanation for their pathogenic mechanism. Blood 81 (1993) 2618-2625
14. Shibata S., Harpel P.C., Gharavi A., et al. Autoantibodies to heparin from patients with antiphospholipid antibody syndrome inhibits formation of antithrombin III-thrombin complexes. Blood 83 (1994) 2532-2540
15. Galli M. Non beta 2-glycoprotein I cofactors for antiphospholipid antibodies. Lupus 5 (1996) 388-392
16. Bowie E.J.W., Thompson J.H., Pascuzzi C.A., et al. Thrombosis in systemic lupus erythematosus despite circulating anticoagulants. J Lab Clin Med 62 (1963) 416-430
17. Alarcon-Segovia D. Clinical manifestations of the antiphospholipid syndrome. J Rheumatol 18 (1992) 1916-1918
18. Triplett D.A. Protean clinical presentation of antiphospholipid-protein antibodies (APA). Thromb Haemost 74 1 (1995) 329
19. She W., Chong B.H., Hogg P.J., et al. Anticardiolipin antibodies block the inhibition of 2 GPI of the factor Xa generating activity of platelets. Thromb Haemost 70 (1993) 342-345
20. Nimpf J., Wurm H., and Kostner G.M. Beta 2 glycoprotein I (apo-H) inhibits the release reaction of human platelets during ADP-induced aggregation. Atherosclerosis 63 (1987) 109-114
21. Maruyama I. Biology of endothelium. Lupus 7 (1998) S41-S43
22. Pierangeli S.S., Coleen-Stanfield M., Liu X., et al. Antiphospholipid antibodies from antiphospholipid syndrome patients' active endothelial cells in vitro and in vivo. Circulation 99 (1999) 1997-2002
23. LeRoux G., Wautier M.P., Guillevin L., et al. IgG binding to endothelial cells in systemic lupus erythematosus. Thromb Haemost 56 (1986) 144-146
24. Hasselaar P., Derksen R.H.W.M., Blokzijl L., et al. Cross reactivity of antibodies directed against cardiolipin, DNA, endothelial cells and blood platelets. Thromb Haemost 63 (1990) 169-173
25. Angles-Cano E., Sultan Y., and Clauvel J.P. Predisposing factors to thrombosis in systemic lupus erythematosus: possible relation to endothelial damage. J Lab Clin Med 94 (1979) 317-323
26. Bidot C.J., JY W., Horstman L.L., et al. Antiphospholipid antibodies and platelet activation as risk factors for thrombosis in thrombocythaemia. Hematology 10 6 (2005) 451-456
27. Levy Y., Shenkman B., Tamarin I., et al. Increased platelet deposition on extracellular matrix under flow conditions in patients with antiphospholipid syndrome who experience thrombotic events. Arthritis Rheum 52 12 (2005) 4011-4017
28. Gavaghan T.P., Krilis S.A., and Daggard G.E. Anticardiolipin antibodies and occlusion of coronary artery bypass grafts. Lancet 2 8565 (1987) 977-978
29. Baker W.F., and Bick R.L. Antiphospholipid antibodies in coronary artery disease: a review. Semin Thromb Hemost 20 1 (1994) 27-45
30. Reverter J.C., Tassies D., Font J., et al. Hypercoagulable state in patients with antiphospholipid syndrome is related to high induced tissue factor expression on monocytes and to low free protein S. Arterioscler Thromb Vasc Biol 16 (1996) 1319-1326
31. Kaburaki J., Kuwana M., Yamamoto M., et al. Clinical significance of anti-annexin V antibodies in patients with systemic lupus erythematosus. Am J Hematol 54 (1997) 209-213
32. Nakamura N., Shidara Y., Kawaguchi N., et al. Lupus anticoagulant autoantibody induces apoptosis in umbilical vein endothelial cells: involvement of annexin V. Biochem Biophys Res Commun 205 (1994) 1488-1493
33. Matsuda J., Gotoh M., Saith M., et al. Anti-annexin antibody in the sera of patients with habitual fetal loss or preeclampsia. Thromb Res 75 (1994) 105-106
34. Carreras L.O., Defreyn G., Machin S.J., et al. Arterial thrombosis, intrauterine death and "lupus" anticoagulant: detection of immunoglobulin interfering with prostacyclin formation. Lancet I 8214 (1981) 244-246
35. Martinuzzo M.E., Maclouf J., Carreras L.O., et al. Antiphospholipid antibodies enhance thrombin induced platelet activation and thromboxane formation. Thromb Haemost 70 (1993) 667-671
36. Rustin M.H.A., Bull H.A., Machin S.J., et al. Effects of lupus anticoagulant in patients with systemic lupus erythematosus on endothelial cells prostacyclin release and procoagulant activity. J Invest Dermatol 90 (1988) 744-748
37. Smirov M.D., Triplett D.A., Comp P.C., et al. On the role of phosphatidylethanolamine in the inhibition of activated protein C activity by antiphospholipid antibodies. J Clin Invest 95 (1995) 309-316
38. Pengo V., Biasiolo A., and Grazia-Fior M. Binding of autoimmune cardiolipin-reactive antibodies to heparin: a mechanism of thrombosis?. Thromb Res 78 5 (1995) 371-378
39. Tannenbaum S.H., Finko R., and Cines D.B. Antibody and immune complexes induce tissue factor production by human endothelial cells. J Immunol 137 (1986) 1532-1537
40. Ryan J., Brett J., Tijburg P., et al. Tumor necrosis factor induced endothelial tissue factor is associated with subendothelial matrix vesicles but is not expressed on the apical surface. Blood 80 (1992) 966-979
41. Brandt J.T. The effects of lupus anticoagulant on the expression of tissue factor activity by cultured endothelial cells. Thromb Haemost 65 (1991) 673
42. Leurs J., Wissing B., Nerme V., et al. Different mechanisms contribute to the biphasic pattern of carboxypeptidase U (TAFIa) generation during in vitro clot lysis in human plasma. Thromb Haemost 89 (2003) 264-271
43. Reutelingsperger C.P., and van Heerde W.L. Annexin V, the regulator of phosphatidylserine-catalyzed inflammation and coagulation during apoptosis. Cell Mol Life Sci 53 (1997) 527-532
44. Warkentin T.E., and Greinacher A. Heparin-induced thrombocytopenia: recognition, treatment, and prevention. Chest 126 (2004) 311S-337S
45. Walenga J.M. Heparin-induced thrombocytopenia and treatment with thrombin inhibitors. Japanese Journal of Thrombosis and Hemostasis 16 6 (2005) 623-640
46. Pouplard C., May M.A., Iochmann S., et al. Antibodies to platelet factor 4 heparin after cardiopulmonary bypass in patients anticoagulated with unfractionated heparin or a low molecular weight heparin: clinical implications for HIT. Circulation 99 (1999) 2530-2536
47. Lindhoff-Last E., Eichler P., Stein M., et al. A prospective study on the incidence and clinical relevance of heparin-induced antibodies in patients after vascular surgery. Thromb Res 97 (2000) 387-393
48. Bauer T.L., Arepally G., Konkle B.A., et al. Prevalence of heparin-associated antibodies without thrombosis in patients undergoing cardiopulmonary bypass surgery. Circulation 95 (1997) 1242-1246
49. Gluckman T.J., Segal J.B., Fredde N.L., et al. Incidence of anti-platelet factor 4/heparin antibody induction in patients undergoing percutaneous coronary revascularization. Am J Cardiol 95 (2005) 744-747
50. Kelton J.G. The pathophysiology of heparin-induced thrombocytopenia. Chest 127 2 (2005) 9S-20S
51. Amiral J., Bridey F., Dreyfus M., et al. PF4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia. Thromb Haemost 68 (1992) 95-96
52. Greinacher A., Pötzsch B., Amiral J., et al. Heparin-associated thrombocytopenia: isolation of the antibody and characterization of a multimolecular PF4-heparin complex as the major antigen. Thromb Haemost 71 (1994) 247-251
53. Amiral J., Wolf M., Fischer A.-M., et al. Pathogenicity of IgA and/or IgM antibodies to heparin-PF4 complexes in patients with heparin-associated thrombocytopenia. Br J Haematol 92 (1996) 954
54. Amiral J., Marfaing-Koka A., Wolf M., et al. Presence of auto-antibodies to interleukin-8 or neutrophil activating peptide-2 in patients with heparin-associated thrombocytopenia. Blood 88 (1996) 410-416
55. Prechel M.M., McDonald M.K., Jeske W.P., et al. Activation of platelets by heparin-induced thrombocytopenia antibodies in the serotonin release assay is not dependent on the presence of heparin. J Thromb Haemost 3 10 (2005) 2168-2175
56. Prechel M.M., Jeske W.P., and Walenga J.M. Platelet-bound PF4 is targeted by HIT antibodies in the absence of heparin. Thromb Haemost 5 Suppl 2 (2007) P-W-336
57. Ahmad S., Haas S., Hoppensteadt D.A., et al. Differential effects of clivarin and heparin in patients undergoing hip and knee surgery for the generation of anti-heparin-platelet factor 4 antibodies. Thromb Res 108 (2003) 49-55
58. Prechel M., Jeske W.P., and Walenga J.M. Laboratory methods for heparin-induced thrombocytopenia. In: Mousa S.A. (Ed). Anticoagulants, antiplatelets, and thrombolytics: methods in molecular medicine (2004), Humana Press, Totowa (NJ) 83-93
59. Jeske W.P., Walenga J.M., Szatkowski E., et al. Effect of glycoprotein IIb/IIIa antagonists on the HIT serum induced activation of platelets. Thromb Res 88 (1997) 271-281
60. Warkentin T.E., Hayward C.P.M., Boshkov L.K., et al. Sera from patients with heparin-induced thrombocytopenia generate platelet-derived microparticles with procoagulant activity: an explanation for the thrombotic complications of heparin-induced thrombocytopenia. Blood 84 (1994) 3691-3699
61. Walenga J.M., Jeske W.P., Prechel M.M., et al. Newer insights on the mechanism of heparin-induced thrombocytopenia. Semin Thromb Hemost 30 Suppl 1 (2004) 57-67
62. Jeske W.P., Vasaiwala S., Schlenker R., et al. Leukocyte activation in heparin-induced thrombocytopenia. Blood 96 11 (2000) 29b
63. Pouplard C., Lochmann S., Renard B., et al. Induction of monocyte tissue factor expression by antibodies to heparin-platelet factor 4 complexes developed in heparin-induced thrombocytopenia. Blood 97 10 (2001) 3300-3302
64. Herbert J.M., Savi P., Jeske W.P., et al. Effect of SR121566A, a potent GPIIb/IIIa antagonist, on the HIT serum/heparin-induced platelet mediated activation of human endothelial cells. Thromb Haemost 80 (1998) 326-331
65. Walenga J.M., Michal K., Hoppensteadt D., et al. Vascular damage correlates between heparin-induced thrombocytopenia and the antiphospholipid syndrome. Clin Appl Thromb Hemost 5 Suppl 1 (1999) S76-S84
66. Fareed J., Walenga J.M., Hoppensteadt D.A., et al. Selectins in the HIT syndrome: pathophysiologic role and therapeutic modulation. Semin Thromb Hemost 25 Suppl 1 (1999) 37-42
67. Blank M., Shoenfeld Y., Tavor S., et al. Anti-platelet factor 4/heparin antibodies from patients with heparin-induced thrombocytopenia provoke direct activation of microvascular endothelial cells. Int Immunol 14 2 (2002) 121-129
68. Visentin G.P., Ford S.E., Scott P.J., et al. Antibodies from patients with heparin-induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells. J Clin Invest 93 (1994) 81-88
69. Suh J.S., Aster R.H., and Visentin G.P. Antibodies from patients with heparin-induced thrombocytopenia recognize different epitopes on heparin:platelet factor 4. Blood 91 (1998) 916-922
70. Walenga J.M., Jeske W.P., and Messmore H.L. Mechanisms of venous and arterial thrombosis in heparin-induced thrombocytopenia. J Thromb Thrombolysis 10 (2000) S13-S20
71. Shames D.S., and Broderick P.A. Catastrophic antiphospholipid antibody syndrome. Conn Med 65 1 (2001) 3-5
72. Hess D. Stroke associated with antiphospholipid antibodies. Stroke 23 Suppl 1 (1992) I23-I28
73. Toschi V., Motta A., Castelli C., et al. High prevalence of antiphospholipid antibodies in young patients with cerebral ischemia of undetermined cause. Stroke 29 9 (1998) 1759-1764
74. Baugh M.J., Prechel M., Hoppensteadt D., et al. The role of CD40 ligand and anti-annexin V antibodies in the pathophysiology of APS and HIT. Blood 96 11 (2000) 272a
75. Lasne D., Saffroy R., Bachelot C., et al. Tests for heparin-induced thrombocytopenia in primary antiphospholipid syndrome. [abstract]. Br J Haematol 97 (1997) 939
76. de Larranaga G., Martinuzzo M., Bocassi A., et al. Heparin-platelet factor 4 induced antibodies in patients with either autoimmune or alloimmune antiphospholipid antibodies. Thromb Haemost 88 (2002) 371-373
77. Martin-Toutain I., Piette J.C., and Diemert M.C. High prevalence of antibodies to platelet factor 4 heparin in patients with antiphospholipid antibodies in absence of heparin-induced thrombocytopenia. Lupus 16 (2007) 79-83
78. Van Kooten C., and Banchereau J. CD40-CD40 ligand. J Leukoc Biol 67 (2000) 2-17
79. Desai-Mehta A., Lu L., Ramsey-Goldman R., et al. Hyperexpression of CD40 ligand by B and T cells in human lupus and its role in pathogenic autoantibody production. J Clin Invest 97 (1996) 2063-2073
80. Koshy M., Berger D., and Crow M.K. Increased expression of CD40 Ligand on systemic lupus erythematosus lymphocytes. J Clin Invest 98 (1996) 826-837